Zargar Abdul Hamid, Bhansali Anil, Majumdar Anirban, Maheshwari Anuj, Bhattacharyya Arpandev, Dasgupta Arundhati, Saboo Banshi Damodarlal, Sethi Bipin Kumar, Sanyal Debmalya, Seshadri Krishna G, Deshpande Neeta Rohit, Kapoor Nitin, Lakhani Om Jitendra, Talwalkar Pradeep Gopal, Kalra Pramila, Mehrotra Rabindera Nath, Sahay Rakesh Kumar, Shukla Rishi, Kant Saket, Das Sambit, Agarwal Sanjay Chunilal, Phatak Sanjeev Ratnakar, G Shanmugasundar, Joshi Shashank Rameshchandra, Shaikh Shehla Sajid, Aravind Sosale Ramachandra, Goswami Soumik, Ghosh Sujoy, Panikar Vijay Kumar, Mohan Viswanathan
Centre for Diabetes and Endocrine Care, Srinagar, India.
Gini Health, Mohali, India.
Diabetes Obes Metab. 2025 Jun;27 Suppl 4(Suppl 4):3-20. doi: 10.1111/dom.16496. Epub 2025 Jun 2.
In India, the increasing prevalence of diabetes and obesity poses a significant threat towards a surge in the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD). Concomitant with the evolving guidelines, there is a need to direct and spread awareness among practicing diabetologists to identify and screen high-risk individuals for MASLD for timely management. Its asymptomatic nature and the evolving guidelines on diagnosis have hindered the precise estimates of MASLD in the high-risk group of individuals in a clinical setting. Therefore, an expert panel of diabetologists from India convened to review, discuss and document the approach towards screening, diagnosis and management of MASLD. Serum biomarkers, simple non-invasive tools and imaging techniques could direct the risk stratification of the patients. Early lifestyle interventions including weight loss and exercise are beneficial. The pharmacological landscape of drugs directed to insulin resistance, lipid metabolism, oxidative stress, inflammation, apoptosis and fibrogenesis pathways for the management of MASLD is expanding. In summary, the consensus statements are expected to serve as a useful guide in the screening and management of MASLD in the region and to direct a well-planned study design that could enhance the scientific value of these statements.
在印度，糖尿病和肥胖症患病率的不断上升对代谢功能障碍相关脂肪性肝病（MASLD，原称非酒精性脂肪性肝病，NAFLD）发病率的激增构成了重大威胁。随着指南的不断演变，有必要在执业糖尿病专家中进行指导并提高认识，以便识别和筛查MASLD的高危个体，从而进行及时管理。其无症状的特性以及不断变化的诊断指南阻碍了在临床环境中对高危个体群体中MASLD的精确估计。因此，来自印度的糖尿病专家组成的一个专家小组召开会议，对MASLD的筛查、诊断和管理方法进行审查、讨论并记录。血清生物标志物、简单的非侵入性工具和成像技术可以指导患者的风险分层。包括减肥和运动在内的早期生活方式干预是有益的。针对胰岛素抵抗、脂质代谢、氧化应激、炎症、细胞凋亡和纤维化途径用于管理MASLD的药物格局正在不断扩大。总之，这些共识声明有望成为该地区MASLD筛查和管理的有用指南，并指导精心规划的研究设计，从而提高这些声明的科学价值。
